BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 280 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 280 shares of BeOne Medicines stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total value of $106,400.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, June 23rd, Xiaobin Wu sold 1,292 shares of BeOne Medicines stock. The stock was sold at an average price of $276.26, for a total value of $356,927.92.
• On Tuesday, June 16th, Xiaobin Wu sold 1,357 shares of BeOne Medicines stock. The stock was sold at an average price of $266.76, for a total value of $361,993.32.
• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The shares were sold at an average price of $261.20, for a total value of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total value of $399,745.08.

BeOne Medicines Stock Down 0.9%

Shares of NASDAQ:ONC opened at $372.49 on Friday. The business’s 50 day moving average is $323.60 and its 200 day moving average is $310.92. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $253.95 and a 12-month high of $385.22. The stock has a market cap of $40.90 billion, a price-to-earnings ratio of 65.58 and a beta of 0.49. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The business had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.66 billion. On average, sell-side analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors have recently added to or reduced their stakes in ONC. Capital International Investors increased its holdings in BeOne Medicines by 1.3% during the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock worth $1,553,909,000 after buying an additional 67,808 shares during the last quarter. Siren L.L.C. boosted its stake in BeOne Medicines by 1.4% in the fourth quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock valued at $151,905,000 after acquiring an additional 7,010 shares during the last quarter. Morgan Stanley boosted its stake in BeOne Medicines by 23.9% in the fourth quarter. Morgan Stanley now owns 437,661 shares of the company’s stock valued at $132,966,000 after acquiring an additional 84,367 shares during the last quarter. Bank of America Corp DE grew its position in shares of BeOne Medicines by 7.0% during the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after acquiring an additional 26,441 shares during the period. Finally, Candriam S.C.A. grew its position in shares of BeOne Medicines by 31.7% during the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after acquiring an additional 62,470 shares during the period. Institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ONC. TD Cowen increased their target price on shares of BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Zacks Research upgraded shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Truist Financial lifted their target price on shares of BeOne Medicines from $416.00 to $418.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their target price on BeOne Medicines from $415.00 to $425.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $402.14.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.